Sepsis is a serious medical condition caused by the body's response to an infection. It affects over 1.5 million people per year in the US and EU, with a mortality rate of 25-30%. Rapid diagnosis is key to treatment, which involves intensive care and can cost over €2,500 per day. Existing diagnostic tests are inadequate. Precysion is developing a new diagnostic tool using genetic biomarkers to predict sepsis risk before symptoms occur, enabling optimized individual treatment. It has the potential to save lives, reduce healthcare costs, and address a multi-billion euro market.
Celltrion is a South Korean biopharmaceutical company established in 2002 that develops, manufactures, and markets biosimilar drugs (highly similar versions of biologic drugs) with the goal of making advanced therapeutics more affordable and accessible to patients worldwide. Their first biosimilar drugs Remsima (infliximab) and Herzuma (trastuzumab) have been approved in multiple countries. Celltrion has extensive R&D, manufacturing, and clinical trial experience that has enabled the successful development and approval of their biosimilar monoclonal antibody drugs. They have a robust pipeline of additional biosimilar candidates in development.
Celltrion Healthcare Company Brochure(2016)celltrionh
Celltrion Healthcare is a biopharmaceutical company committed to developing and distributing more affordable biosimilar therapies. It has been developing biosimilar products since 1999 to increase patient access to treatments. Celltrion specializes in research and development of monoclonal antibodies and biologics, while Celltrion Healthcare conducts worldwide marketing, sales, and distribution. Their biosimilar products have been approved in over 70 countries. Celltrion is devoted to developing novel biologics and high-quality biosimilar monoclonal antibodies to increase global healthcare access.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
2013 US Tumor Marker Testing Market: Opportunities and Strategies for SupplierReportsnReports
This 620-page report provides a comprehensive analysis of the US tumor marker testing market, including cancer statistics, current and emerging diagnostic tests, instrumentation technologies, test volume and sales forecasts through 2023 for various market segments. It highlights major opportunities for suppliers in reagent kits, instrumentation, automation, and software. The report profiles current and emerging suppliers and provides strategic recommendations to support business strategies.
This lecture details the science of sepsis care in 2015 with compliments to the multiple online sources used, some of which are other lectures on SlideShare.
Celltrion is a South Korean biopharmaceutical company established in 2002 that develops, manufactures, and markets biosimilar drugs (highly similar versions of biologic drugs) with the goal of making advanced therapeutics more affordable and accessible to patients worldwide. Their first biosimilar drugs Remsima (infliximab) and Herzuma (trastuzumab) have been approved in multiple countries. Celltrion has extensive R&D, manufacturing, and clinical trial experience that has enabled the successful development and approval of their biosimilar monoclonal antibody drugs. They have a robust pipeline of additional biosimilar candidates in development.
Celltrion Healthcare Company Brochure(2016)celltrionh
Celltrion Healthcare is a biopharmaceutical company committed to developing and distributing more affordable biosimilar therapies. It has been developing biosimilar products since 1999 to increase patient access to treatments. Celltrion specializes in research and development of monoclonal antibodies and biologics, while Celltrion Healthcare conducts worldwide marketing, sales, and distribution. Their biosimilar products have been approved in over 70 countries. Celltrion is devoted to developing novel biologics and high-quality biosimilar monoclonal antibodies to increase global healthcare access.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
2013 US Tumor Marker Testing Market: Opportunities and Strategies for SupplierReportsnReports
This 620-page report provides a comprehensive analysis of the US tumor marker testing market, including cancer statistics, current and emerging diagnostic tests, instrumentation technologies, test volume and sales forecasts through 2023 for various market segments. It highlights major opportunities for suppliers in reagent kits, instrumentation, automation, and software. The report profiles current and emerging suppliers and provides strategic recommendations to support business strategies.
This lecture details the science of sepsis care in 2015 with compliments to the multiple online sources used, some of which are other lectures on SlideShare.
Executive Summary 2009 Project Continuation With Picsguestcbe9f3
The document summarizes GlobalMed Technologies, a company that developed an ultraviolet light blood irradiation system to treat HIV/AIDS. It details the need for alternative treatments given drug resistance issues. The system was tested in clinical trials in the Dominican Republic that significantly reduced viral loads and increased life expectancy. GlobalMed is seeking funding to conduct phase 2 clinical trials in Colombia on 200 patients to further validate the treatment and ultimately seek approval and market it globally as a more effective and lower-cost alternative to existing antiretroviral drugs.
Executive Summary 2009 Project Continuation With Picsguestcbe9f3
The document summarizes GlobalMed Technologies, a company that developed an ultraviolet light blood irradiation system to treat HIV/AIDS. It details the need for alternative treatments given drug resistance issues. The system was tested in clinical trials in the Dominican Republic that significantly reduced viral loads and increased life expectancy. GlobalMed is seeking funding to conduct phase 2 clinical trials in Colombia on 200 patients to further validate the treatment and ultimately seek approval and market it globally as a more effective and lower-cost alternative to existing antiretroviral drugs.
Quantum Immunologics (QI) is dedicated to the research, development and production of products and services that will promote immunologic cancer treatments and cancer detection technologies.
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...Laura Berry
Presented at the 4th Microbiome R&D and Business Collaboration Forum: USA. To find out more, visit: www.global-engage.com
Greg Kuehn, President and COO of Metabiomics, presents the MB-01 colorectal adenoma clinical research study, sequencing technology and microbiome diagnostics platform.
Inovio Pharmaceuticals, Inc. Corporate Presentation December 2013Company Spotlight
This document summarizes information presented by Dr. J. Joseph Kim, President and CEO of Inovio Pharmaceuticals, Inc. It discusses Inovio's DNA immunotherapy technology, clinical programs, partnerships, leadership, and upcoming value drivers. Key points include:
- Inovio is developing DNA-based immunotherapies delivered using electroporation for cancers and infectious diseases.
- Their lead program, VGX-3100 for HPV-related cancers, has shown strong T-cell responses and is in Phase II trials with efficacy data expected in mid-2014.
- Inovio has partnerships with Roche for prostate cancer and hepatitis B therapies and external funding to support several clinical programs.
This document provides an overview of Inovio Pharmaceuticals and their DNA immunotherapy technology. Some key points:
- Inovio is developing DNA immunotherapies to generate targeted immune responses to prevent and treat cancers and infectious diseases. Their lead product VGX-3100 is in Phase II trials for HPV-associated precancers.
- Their approach uses optimized synthetic consensus DNA plasmids delivered intramuscularly with electroporation to produce targeted antigen-specific T-cell responses. This has shown best-in-class T cell responses in clinical trials.
- Upcoming milestones include Phase II efficacy data for VGX-3100 in mid-2014, additional cancer vaccine
EuroBioForum 2013 - Day 2 | Frank MolinaEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
EuroBioMed, France:
Private-public collaborations to boost open innovation
Dr Franck Molina
President of EDCA, Chair of diagnosis group of Eurobiomed
Director of Sysdiag
=======================================
http://www.eurobioforum.eu
HealthBIO 2020 Aino Kalervo Tilt BiotherapeuticsBusiness Turku
TILT Biotherapeutics develops oncolytic immunotherapies to enable T cell therapies and checkpoint inhibitors. Its lead product TILT-123, a cytokine-armed oncolytic virus, has shown 100% cure rates in vivo and is currently in a Phase 1 clinical trial in Europe. TILT aims to explore licensing agreements to support the commercialization of its pipeline of oncolytic viruses, which have the potential to make T cell therapies and checkpoint inhibitors more effective for cancer treatment. The company has a strong international team and funding to advance its clinical programs through 2022.
Medicare Advantage Ad - Screening Patients with Risk FactorsChristian Trygstad
This was created to support the use of PADnet in the Medicare Advantage space by screening all patients with risk factors for peripheral artery disease
CHLA Pediatric Health Investment Opportunities_Sept 16Jessica Rousset
This document provides information on investment opportunities in pediatric health at a leading pediatric academic medical center. It summarizes the center's patient population and annual statistics, lists several interdisciplinary centers focused on critical pediatric health issues, describes the research institute including NIH funding and clinical trials, and provides information on the center for innovation and several startup companies with pediatric health technologies.
While many companies are contributing to the battle against the pandemic, Deep Tech startups are trying to overcome scientific challenges to help with prevention, testing or treatment in novel and scalable ways.
This live event organized by SOSV brings together investors who have backed dozens of relevant startups, to get a sense of:
- The variety of solutions being developed,
- Their potential outcomes,
- The broader role and opportunities of deep tech investment.
SPEAKERS
- Seth Bannon, Founding Partner, Fifty Years
- Jun Axup, PhD, Chief Science Officer & Partner, IndieBio / SOSV
- Alex Morgan, MD PhD, Partner, Khosla Ventures
MODERATORS
- Julie Wolf, PhD, Communications Director, IndieBio / SOSV
- Benjamin Joffe, Partner, SOSV
COVID-19 PORTFOLIO
- Fifty Years: www.fifty.vc/covid
- SOSV: www.sosv.com/covid-startups/
- Khosla Ventures: www.khoslaventures.com/khosla-ventures-entrepreneurs-are-responding-with-amazing-diversity-to-covid-19-solutions-for-societys-needs
This document provides information on two pre-conference workshops at the "Superbugs & Superdrugs" conference on combating antimicrobial resistance.
The first workshop discusses rapid diagnostic tools for infectious diseases, focusing on tracking emerging infections, state-of-the-art diagnostic methods, mobile applications, and challenges in diagnosis.
The second workshop examines how antimicrobial copper touch surfaces can improve patient outcomes and reduce costs by lowering healthcare-associated infections and antimicrobial resistance. It will evaluate the evidence supporting copper's use and discuss cost-benefit analysis and practical implementation.
This document provides information on two pre-conference workshops at the "Superbugs & Superdrugs" conference on combating antimicrobial resistance.
The first workshop discusses rapid diagnostic tools for infectious diseases, focusing on tracking emerging infections, state-of-the-art diagnostic methods, mobile applications, and challenges in diagnosis.
The second workshop examines making materials like copper touch surfaces in healthcare settings to improve patient outcomes and reduce costs by lowering infection rates and antimicrobial resistance. It will evaluate the evidence for copper's antimicrobial efficacy and cost-benefit analysis.
The document discusses four paradoxes of managing high growth biotech ventures:
1) Breakthrough intellectual property often comes from outside the target industry or slow-moving organizations.
2) Entrepreneurship requires individual courage but is also a team sport.
3) Financing covers near-term milestones but companies must plan for the long-term.
4) Plans rarely survive but planning is critical to success.
Inovio is developing DNA-based immunotherapies and vaccines to treat cancer and infectious diseases. Their lead product VGX-3100 met primary and secondary endpoints in a Phase II cervical dysplasia trial. Inovio has multiple cancer and infectious disease products in development and partnerships with AstraZeneca and Roche worth over $1 billion in potential milestones. They are pursuing DNA-based monoclonal antibody products and have over $100 million in non-dilutive funding supporting their vaccine programs.
Targovax is developing immunotherapies to enable the immune system to kill cancer cells. They have two platforms: oncolytic viruses and peptide vaccines. Their peptide vaccine TG01 showed encouraging 2-year survival data in a Phase I/II trial in pancreatic cancer patients, with a survival rate higher than historical controls. Their oncolytic virus ONCOS-102 is in a Phase I trial in CPI-refractory melanoma patients to see if it can activate the immune system and make those patients responsive to checkpoint inhibitors again. Targovax has multiple clinical readouts expected in 2017 and 2018 that could be value inflection points.
The document discusses the safety and supply of plasma-derived hemophilia products. It outlines how fractionation advances in the 1960s-1970s enabled treatment to free hemophiliacs. Both plasma-derived and recombinant products are important, with no single supply sufficient. Industry standards have reduced pathogen risks through donor selection, testing, and viral clearance steps. Emerging pathogens like West Nile virus require ongoing vigilance. While risks are low, vCJD transmission through plasma products remains a concern addressed through geographic deferrals and manufacturing clearance. Increasing global product demand challenges adequate supply for all patients.
This document discusses a new technology for early lung cancer detection using breath analysis. It begins by noting that lung cancer is a major killer, with most cases detected at late stages. Existing screening methods like CT scans are expensive, introduce radiation risk, and are only approved for high-risk groups. The technology described aims to provide inexpensive, instant breath tests to detect lung cancer at earlier stages. It discusses the company's proprietary liquid concentrator and sensor technologies, as well as plans for clinical trials and FDA approval to bring the product to market as a screening and diagnostic tool.
Executive Summary 2009 Project Continuation With Picsguestcbe9f3
The document summarizes GlobalMed Technologies, a company that developed an ultraviolet light blood irradiation system to treat HIV/AIDS. It details the need for alternative treatments given drug resistance issues. The system was tested in clinical trials in the Dominican Republic that significantly reduced viral loads and increased life expectancy. GlobalMed is seeking funding to conduct phase 2 clinical trials in Colombia on 200 patients to further validate the treatment and ultimately seek approval and market it globally as a more effective and lower-cost alternative to existing antiretroviral drugs.
Executive Summary 2009 Project Continuation With Picsguestcbe9f3
The document summarizes GlobalMed Technologies, a company that developed an ultraviolet light blood irradiation system to treat HIV/AIDS. It details the need for alternative treatments given drug resistance issues. The system was tested in clinical trials in the Dominican Republic that significantly reduced viral loads and increased life expectancy. GlobalMed is seeking funding to conduct phase 2 clinical trials in Colombia on 200 patients to further validate the treatment and ultimately seek approval and market it globally as a more effective and lower-cost alternative to existing antiretroviral drugs.
Quantum Immunologics (QI) is dedicated to the research, development and production of products and services that will promote immunologic cancer treatments and cancer detection technologies.
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...Laura Berry
Presented at the 4th Microbiome R&D and Business Collaboration Forum: USA. To find out more, visit: www.global-engage.com
Greg Kuehn, President and COO of Metabiomics, presents the MB-01 colorectal adenoma clinical research study, sequencing technology and microbiome diagnostics platform.
Inovio Pharmaceuticals, Inc. Corporate Presentation December 2013Company Spotlight
This document summarizes information presented by Dr. J. Joseph Kim, President and CEO of Inovio Pharmaceuticals, Inc. It discusses Inovio's DNA immunotherapy technology, clinical programs, partnerships, leadership, and upcoming value drivers. Key points include:
- Inovio is developing DNA-based immunotherapies delivered using electroporation for cancers and infectious diseases.
- Their lead program, VGX-3100 for HPV-related cancers, has shown strong T-cell responses and is in Phase II trials with efficacy data expected in mid-2014.
- Inovio has partnerships with Roche for prostate cancer and hepatitis B therapies and external funding to support several clinical programs.
This document provides an overview of Inovio Pharmaceuticals and their DNA immunotherapy technology. Some key points:
- Inovio is developing DNA immunotherapies to generate targeted immune responses to prevent and treat cancers and infectious diseases. Their lead product VGX-3100 is in Phase II trials for HPV-associated precancers.
- Their approach uses optimized synthetic consensus DNA plasmids delivered intramuscularly with electroporation to produce targeted antigen-specific T-cell responses. This has shown best-in-class T cell responses in clinical trials.
- Upcoming milestones include Phase II efficacy data for VGX-3100 in mid-2014, additional cancer vaccine
EuroBioForum 2013 - Day 2 | Frank MolinaEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
EuroBioMed, France:
Private-public collaborations to boost open innovation
Dr Franck Molina
President of EDCA, Chair of diagnosis group of Eurobiomed
Director of Sysdiag
=======================================
http://www.eurobioforum.eu
HealthBIO 2020 Aino Kalervo Tilt BiotherapeuticsBusiness Turku
TILT Biotherapeutics develops oncolytic immunotherapies to enable T cell therapies and checkpoint inhibitors. Its lead product TILT-123, a cytokine-armed oncolytic virus, has shown 100% cure rates in vivo and is currently in a Phase 1 clinical trial in Europe. TILT aims to explore licensing agreements to support the commercialization of its pipeline of oncolytic viruses, which have the potential to make T cell therapies and checkpoint inhibitors more effective for cancer treatment. The company has a strong international team and funding to advance its clinical programs through 2022.
Medicare Advantage Ad - Screening Patients with Risk FactorsChristian Trygstad
This was created to support the use of PADnet in the Medicare Advantage space by screening all patients with risk factors for peripheral artery disease
CHLA Pediatric Health Investment Opportunities_Sept 16Jessica Rousset
This document provides information on investment opportunities in pediatric health at a leading pediatric academic medical center. It summarizes the center's patient population and annual statistics, lists several interdisciplinary centers focused on critical pediatric health issues, describes the research institute including NIH funding and clinical trials, and provides information on the center for innovation and several startup companies with pediatric health technologies.
While many companies are contributing to the battle against the pandemic, Deep Tech startups are trying to overcome scientific challenges to help with prevention, testing or treatment in novel and scalable ways.
This live event organized by SOSV brings together investors who have backed dozens of relevant startups, to get a sense of:
- The variety of solutions being developed,
- Their potential outcomes,
- The broader role and opportunities of deep tech investment.
SPEAKERS
- Seth Bannon, Founding Partner, Fifty Years
- Jun Axup, PhD, Chief Science Officer & Partner, IndieBio / SOSV
- Alex Morgan, MD PhD, Partner, Khosla Ventures
MODERATORS
- Julie Wolf, PhD, Communications Director, IndieBio / SOSV
- Benjamin Joffe, Partner, SOSV
COVID-19 PORTFOLIO
- Fifty Years: www.fifty.vc/covid
- SOSV: www.sosv.com/covid-startups/
- Khosla Ventures: www.khoslaventures.com/khosla-ventures-entrepreneurs-are-responding-with-amazing-diversity-to-covid-19-solutions-for-societys-needs
This document provides information on two pre-conference workshops at the "Superbugs & Superdrugs" conference on combating antimicrobial resistance.
The first workshop discusses rapid diagnostic tools for infectious diseases, focusing on tracking emerging infections, state-of-the-art diagnostic methods, mobile applications, and challenges in diagnosis.
The second workshop examines how antimicrobial copper touch surfaces can improve patient outcomes and reduce costs by lowering healthcare-associated infections and antimicrobial resistance. It will evaluate the evidence supporting copper's use and discuss cost-benefit analysis and practical implementation.
This document provides information on two pre-conference workshops at the "Superbugs & Superdrugs" conference on combating antimicrobial resistance.
The first workshop discusses rapid diagnostic tools for infectious diseases, focusing on tracking emerging infections, state-of-the-art diagnostic methods, mobile applications, and challenges in diagnosis.
The second workshop examines making materials like copper touch surfaces in healthcare settings to improve patient outcomes and reduce costs by lowering infection rates and antimicrobial resistance. It will evaluate the evidence for copper's antimicrobial efficacy and cost-benefit analysis.
The document discusses four paradoxes of managing high growth biotech ventures:
1) Breakthrough intellectual property often comes from outside the target industry or slow-moving organizations.
2) Entrepreneurship requires individual courage but is also a team sport.
3) Financing covers near-term milestones but companies must plan for the long-term.
4) Plans rarely survive but planning is critical to success.
Inovio is developing DNA-based immunotherapies and vaccines to treat cancer and infectious diseases. Their lead product VGX-3100 met primary and secondary endpoints in a Phase II cervical dysplasia trial. Inovio has multiple cancer and infectious disease products in development and partnerships with AstraZeneca and Roche worth over $1 billion in potential milestones. They are pursuing DNA-based monoclonal antibody products and have over $100 million in non-dilutive funding supporting their vaccine programs.
Targovax is developing immunotherapies to enable the immune system to kill cancer cells. They have two platforms: oncolytic viruses and peptide vaccines. Their peptide vaccine TG01 showed encouraging 2-year survival data in a Phase I/II trial in pancreatic cancer patients, with a survival rate higher than historical controls. Their oncolytic virus ONCOS-102 is in a Phase I trial in CPI-refractory melanoma patients to see if it can activate the immune system and make those patients responsive to checkpoint inhibitors again. Targovax has multiple clinical readouts expected in 2017 and 2018 that could be value inflection points.
The document discusses the safety and supply of plasma-derived hemophilia products. It outlines how fractionation advances in the 1960s-1970s enabled treatment to free hemophiliacs. Both plasma-derived and recombinant products are important, with no single supply sufficient. Industry standards have reduced pathogen risks through donor selection, testing, and viral clearance steps. Emerging pathogens like West Nile virus require ongoing vigilance. While risks are low, vCJD transmission through plasma products remains a concern addressed through geographic deferrals and manufacturing clearance. Increasing global product demand challenges adequate supply for all patients.
This document discusses a new technology for early lung cancer detection using breath analysis. It begins by noting that lung cancer is a major killer, with most cases detected at late stages. Existing screening methods like CT scans are expensive, introduce radiation risk, and are only approved for high-risk groups. The technology described aims to provide inexpensive, instant breath tests to detect lung cancer at earlier stages. It discusses the company's proprietary liquid concentrator and sensor technologies, as well as plans for clinical trials and FDA approval to bring the product to market as a screening and diagnostic tool.
Similar to Precysion Glss Presentation Oct Pm2 (20)
5. “ PRECYSION” A Paradigm Shift Patent Pending Diagnostic and Prognositc Tool Using Genetic Biomarkers (Cytokine Gene Expression). Developed by St James Hospital & Trinity College Dublin To screen patients & accurately predict those susceptible to Sepsis post surgery. Majority will tolerate infection without critical illness. To optimise individual treatment, care stratification. Identify groups with Sepsis at low, intermediate & high risk.
6.
7.
8.
9.
10.
11.
12. Save Lives/Reduce Healthcare Costs In Multi-Billion Market JV & Investment Partner Needed! Phase 1 ; €0.5m EU Market Prototype Phase 2; €3.5m Enter US Market PoC (EI/TCD) Oct ‘09
Editor's Notes
Good day! Thank you for your attention. Today I would like to introduce you to my project on the EI Business Partner programme in collaboration with research work from St James Hospital and TCD.
Sepsis is an overwhelming systemic inflammatory response to infection such as pneumonia, urinary tract, wound or skin leading to blood poisoning, chronic organ failure and death in 30% of cases. 2~3 people in every 1,000 of our population develop Sepsis and 1,400 die daily from it. In America historically the number of cases of Sepsis are 750,000 pa with Europe having equivalent figures. US hospital records from 1979 to 2000 show that Sepsis is on the rise at 13% pa due to wider invasive surgical procedures, more resistant micro organisms, more suppressed immune systems and an ever aging population.
Both in human life and healthcare resource terms Sepsis is a costly illness with an annual cost to Western economies estimated at €45 billion. Sepsis is currently very difficult to diagnose and differentiate from other forms of critical illness and bacterial infection. Rapid and accurate diagnosis is key to patient outcome with cautious GP’s and Consultants admitting patients to the ICU unit for monitoring. The average cost per patient admitted to ICU is €2,500 per day for an average stay of 20 days in excess of €50,000 when drug treatments at €10,000 plus are added in. Survivors can spend up to a year or more in care. Only 50% fully recover. Insurance re-imbursement costs are also an issue in the case of misdiagnosis.
So what is missing right now! Opinion leaders agree that the number of Sepsis cases is increasing and that the rate of mortality is staying stubbornly high at 25~30%. The current tests are not working to reduce the levels and the costs of Sepsis treatment, rather they are designed only to detect the source of the infection post onset when the patient has reached a critical stage of treatment. What is now needed is a test based on genetic biomarkers that tracks a person’s genetic susceptibility, state of immune system strength and coexisting complications in other to define an accurate prognosis.
Today I am pleased to introduce you to Precysion a patent pending Diagnostic and Prognostic Tool based on Genetic Biomarkers from TCD and St James that accurately predicts those at greater risk of succumbing to Sepsis. In the majority of cases patients will tolerate infection without succumbing to critical illness but the difficulty is identifying those with Sepsis once fever and other symptoms show. Precysion accurately measures the levels and ratios of immune system proteins called cytokines which orchestrate the bodies pro-inflammatory and anti-inflammatory defences. The studies at St James Hospital show that the ratio of cytokines such as TNF Alpha, Interferon Gamma and various Interleukins accurately identify those patient groups who will tolerate infection without becoming critically ill. Furthermore in those who do develop overwhelming illness the test is able to identify those groups at low risk, intermediate risk and high risk of death. In some cases the likelihood of developing critical illness is 9~10 times greater than the average.
The market for genetic biomarkers is growing at 18% per annum and is expected to reach $12.7 billion in 2012. Of this the market for diagnostic applications is expected to reach $5,15 billion in 2012. Other diagnostic applications include HIV, Hepatitus, Meningitus and TB. The number of Sepsis cases in the US is expected to reach one million in 2010 with an average ICU cost of $30,000 +. The European market is similar. For each case of a patient presenting with Sepsis there may be a factor of 3~4 presenting with infection who do not develop Sepsis but who still require investigation, testing and therapy. Therefore the potential market for a Sepsis kit test in hospitals not including clinical trials and drug development is 8 million kits in the US & EU. /if we look at the cost per test for a Sepsis pathogen detection product such as Septifast which is marketed at $180 we could expect to a similar price of €150 for Precysion. This would lead to a potential market for hospital kits of €12 Billion.
Obtain “Proof of Concept” data later this month. Verify route to market with hospital testing protocols, lab equipment platforms, EU & US validation procedures. Establish spin out company. Reduce the current 20+ step lab process to a commercial test kit prototype. Check out platform partners and prospective JV partners. Go to market in the next 2~3 years.
Dr Thomas Ryan is the Consultant Anaesethist in charge of accident and emergency care in St James Hospital. He and his research team are the founders of the technology. Tom has also spent time as a fellow in the famous Cleveland Clinic in Ohio. Dr John Thornback is an expert in “Genetic Biomarkers” and Nuclear Science. John worked with Professor Sir Geoffrey Wilkinson who won the Nobel Prize for Chemistry and his work on atomic science in the 70’s. John has worked at Harvard University and MIT and has been active in the COO and CSO role in a number of multinational and start up diagnostic companies. Bruce Murdoch is a colleague of mine who as acted as VP and MD for a number of multinational and start up biopharma and diagnostic companies. Ono of his roles with Bioaccelerate Inc. a $120 million turnover company was to identify, fund and advise suitable biotech start up projects. Clive Kendall qualified with Deloitte Plender Griffiths, and gained further experience at Hill Samuel and Arthur Andersen. He has been Finance Director of two Companies listed on the London Stock Exchange. As a business advisor and an Interim Manager he has had significant senior level involvement with businesses ranging from start up to £500m turnover, both private and public. I myself have been involved in start up companies since I graduated and received a scholarship to Japan in the late eighties. I was part of the start up team for 2 Japanese mfg facilities in the UK. I went on to start up a systems integration business in Dublin which was sold for €9 million in 2000. I went on to work with 5 start up companies in the life sciences arena including diagnostics, stem cell storage and manufacturing control systems.
Speak about what phase one and two are with this slide.